1.
WHO: recommended definitions, terminology and format for statistical tables
related to the perinatal period and use of a new certificate for cause of perinatal
deaths. Modifications recommended by FIGO as amended October 14, 1976.
Acta Obstet Gynecol Scand 56, 247-253 (1977).
2.
UNICEF, W., World Bank Group and United Nations Levels and Trends in Child
Mortality Report 2017. UNICEF (2017).
3.
Liu, L. et al. Global, regional, and national causes of under-5 mortality in 200015: an updated systematic analysis with implications for the Sustainable
Development Goals. Lancet 388, 3027-3035 (2016).
4.
Luu, T.M., Rehman Mian, M.O. & Nuyt, A.M. Long-Term Impact of Preterm
Birth: Neurodevelopmental and Physical Health Outcomes. Clin Perinatol 44,
305-314 (2017).
5.
Raju, T.N.K. et al. Long-Term Healthcare Outcomes of Preterm Birth: An
Executive Summary of a Conference Sponsored by the National Institutes of
Health. J Pediatr 181, 309-318.e301 (2017).
6.
Bolton, C.E., Bush, A., Hurst, J.R., Kotecha, S. & McGarvey, L. Lung
consequences in adults born prematurely. Thorax 70, 574-580 (2015).
86
7.
de Jong, F., Monuteaux, M.C., van Elburg, R.M., Gillman, M.W. & Belfort,
M.B. Systematic review and meta-analysis of preterm birth and later systolic
blood pressure. Hypertension 59, 226-234 (2012).
8.
de Jong, M., Verhoeven, M. & van Baar, A.L. School outcome, cognitive
functioning, and behaviour problems in moderate and late preterm children and
adults: a review. Semin Fetal Neonatal Med 17, 163-169 (2012).
9.
Kajantie, E. et al. Insulin sensitivity and secretory response in adults born
preterm: the Helsinki Study of Very Low Birth Weight Adults. J Clin Endocrinol
Metab 100, 244-250 (2015).
10.
Lawlor, D.A., Ronalds, G., Clark, H., Smith, G.D. & Leon, D.A. Birth weight is
inversely associated with incident coronary heart disease and stroke among
individuals born in the 1950s: findings from the Aberdeen Children of the 1950s
prospective cohort study. Circulation 112, 1414-1418 (2005).
11.
Romero, R., Dey, S.K. & Fisher, S.J. Preterm labor: one syndrome, many causes.
Science (New York, N.Y.) 345, 760-765 (2014).
12.
Goldenberg, R.L., Hauth, J.C. & Andrews, W.W. Intrauterine infection and
preterm delivery. N Engl J Med 342, 1500-1507 (2000).
87
13.
Torbé, A. & Czajka, R. Proinflammatory cytokines and other indications of
inflammation in cervico-vaginal secretions and preterm delivery. Int J Gynaecol
Obstet 87, 125-130 (2004).
14.
Døllner, H., Vatten, L., Halgunset, J., Rahimipoor, S. & Austgulen, R. Histologic
chorioamnionitis and umbilical serum levels of pro-inflammatory cytokines and
cytokine inhibitors. Bjog 109, 534-539 (2002).
15.
Romero, R. et al. The role of infection in preterm labour and delivery. Paediatr
Perinat Epidemiol 15 Suppl 2, 41-56 (2001).
16.
Harris, A.N., Perlman, M., Schiller, S.L., Romero, R. & Mitchell, M.D.
Characterization of prostaglandin production in amnion-derived WISH cells. Am
J Obstet Gynecol 159, 1385-1389 (1988).
17.
Romero, R., Hobbins, J.C. & Mitchell, M.D. Endotoxin stimulates prostaglandin
E2 production by human amnion. Obstet Gynecol 71, 227-228 (1988).
18.
Gibbs, R.S. Chorioamnionitis and bacterial vaginosis. Am J Obstet Gynecol 169,
460-462 (1993).
19.
Steinborn, A. et al. Cytokine release from placental endothelial cells, a process
associated with preterm labour in the absence of intrauterine infection. Cytokine
11, 66-73 (1999).
88
20.
Smith, W.L., Urade, Y. & Jakobsson, P.J. Enzymes of the cyclooxygenase
pathways of prostanoid biosynthesis. Chem Rev 111, 5821-5865 (2011).
21.
Herschman, H.R. Prostaglandin synthase 2. Biochim Biophys Acta 1299, 125140 (1996).
22.
Flores-Díaz, M., Monturiol-Gross, L., Naylor, C., Alape-Girón, A. & Flieger, A.
Bacterial Sphingomyelinases and Phospholipases as Virulence Factors.
Microbiol Mol Biol Rev 80, 597-628 (2016).
23.
Delmis, J. Placental lipid contents in preterm labor complicated by
chorioamnionitis. J Perinat Med 17, 417-422 (1989).
24.
Romero, R. et al. Infection in the pathogenesis of preterm labor. Semin Perinatol
12, 262-279 (1988).
25.
Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W. & Herschman, H.R.
TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells,
encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol
Chem 266, 12866-12872 (1991).
26.
Morita, I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid
Mediat 68-69, 165-175 (2002).
89
27.
Blencowe, H. et al. National, regional, and worldwide estimates of preterm birth
rates in the year 2010 with time trends since 1990 for selected countries: a
systematic analysis and implications. Lancet 379, 2162-2172 (2012).
28.
Yorifuji, T. et al. Trends of preterm birth and low birth weight in Japan: a one
hospital-based study. BMC Pregnancy Childbirth 12, 162 (2012).
29.
Simhan, H.N. & Caritis, S.N. Prevention of preterm delivery. N Engl J Med 357,
477-487 (2007).
30.
Haas, D.M., Caldwell, D.M., Kirkpatrick, P., McIntosh, J.J. & Welton, N.J.
Tocolytic therapy for preterm delivery: systematic review and network metaanalysis. Bmj 345, e6226 (2012).
31.
Haas, D.M. et al. Tocolytic therapy: a meta-analysis and decision analysis.
Obstet Gynecol 113, 585-594 (2009).
32.
Niebyl, J.R. et al. The inhibition of premature labor with indomethacin.
American journal of obstetrics and gynecology 136, 1014-1019 (1980).
33.
Zuckerman, H., Shalev, E., Gilad, G. & Katzuni, E. Further study of the
inhibition of premature labor by indomethacin. Part II double-blind study. J
Perinat Med 12, 25-29 (1984).
90
34.
Besinger, R.E., Niebyl, J.R., Keyes, W.G. & Johnson, T.R. Randomized
comparative trial of indomethacin and ritodrine for the long-term treatment of
preterm labor. Am J Obstet Gynecol 164, 981-986; discussion 986-988 (1991).
35.
Kurki, T., Eronen, M., Lumme, R. & Ylikorkala, O. A randomized doubledummy comparison between indomethacin and nylidrin in threatened preterm
labor. Obstet Gynecol 78, 1093-1097 (1991).
36.
Morales, W.J., Smith, S.G., Angel, J.L., O'Brien, W.F. & Knuppel, R.A. Efficacy
and safety of indomethacin versus ritodrine in the management of preterm labor:
a randomized study. Obstet Gynecol 74, 567-572 (1989).
37.
Morales, W.J. & Madhav, H. Efficacy and safety of indomethacin compared with
magnesium sulfate in the management of preterm labor: a randomized study. Am
J Obstet Gynecol 169, 97-102 (1993).
38.
Moise, K.J., Jr. et al. Placental transfer of indomethacin in the human pregnancy.
American journal of obstetrics and gynecology 162, 549-554 (1990).
39.
Huhta, J.C. et al. Detection and quantitation of constriction of the fetal ductus
arteriosus by Doppler echocardiography. Circulation 75, 406-412 (1987).
91
40.
Moise, K.J., Jr. Effect of advancing gestational age on the frequency of fetal
ductal constriction in association with maternal indomethacin use. American
journal of obstetrics and gynecology 168, 1350-1353 (1993).
41.
Rasanen, J. & Jouppila, P. Fetal cardiac function and ductus arteriosus during
indomethacin and sulindac therapy for threatened preterm labor: a randomized
study. American journal of obstetrics and gynecology 173, 20-25 (1995).
42.
Griffiths, S.K. & Campbell, J.P. Placental structure, function and drug transfer.
Continuing Education in Anaesthesia Critical Care & Pain 15, 84-89 (2015).
43.
Pacifici, G.M. & Nottoli, R. Placental transfer of drugs administered to the
mother. Clin Pharmacokinet 28, 235-269 (1995).
44.
Refuerzo, J.S. et al. Liposomes: a nanoscale drug carrying system to prevent
indomethacin passage to the fetus in a pregnant mouse model. American journal
of obstetrics and gynecology 212, 508 e501-507 (2015).
45.
Paul, J.W. et al. Drug delivery to the human and mouse uterus using
immunoliposomes targeted to the oxytocin receptor. Am J Obstet Gynecol 216,
283 e281-283 e214 (2017).
46.
Refuerzo, J.S. et al. Uterus-targeted liposomes for preterm labor management:
studies in pregnant mice. Sci Rep 6, 34710 (2016).
92
47.
Bré, L.P., Zheng, Y., Pêgo, A.P. & Wang, W. Taking tissue adhesives to the
future: from traditional synthetic to new biomimetic approaches. Biomaterials
Science 1, 239-253 (2013).
48.
Suk, J.S., Xu, Q., Kim, N., Hanes, J. & Ensign, L.M. PEGylation as a strategy
for improving nanoparticle-based drug and gene delivery. Advanced drug
delivery reviews 99, 28-51 (2016).
49.
Veronese, F.M. & Pasut, G. PEGylation, successful approach to drug delivery.
Drug discovery today 10, 1451-1458 (2005).
50.
Alconcel, S.N.S., Baas, A.S. & Maynard, H.D. FDA-approved poly(ethylene
glycol)–protein conjugate drugs. Polymer Chemistry 2, 1442-1448 (2011).
51.
Yamashita, K. et al. Silica and titanium dioxide nanoparticles cause pregnancy
complications in mice. Nature nanotechnology 6, 321-328 (2011).
52.
Huang, J.P. et al. Nanoparticles can cross mouse placenta and induce trophoblast
apoptosis. Placenta 36, 1433-1441 (2015).
53.
Grafmueller, S. et al. Bidirectional Transfer Study of Polystyrene Nanoparticles
across the Placental Barrier in an ex Vivo Human Placental Perfusion Model.
Environmental health perspectives 123, 1280-1286 (2015).
93
54.
Chu, M. et al. Transfer of quantum dots from pregnant mice to pups across the
placental barrier. Small (Weinheim an der Bergstrasse, Germany) 6, 670-678
(2010).
55.
Elovitz, M.A. & Mrinalini, C. Animal models of preterm birth. Trends
Endocrinol Metab 15, 479-487 (2004).
56.
Buhimschi, I.A., Buhimschi, C.S. & Weiner, C.P. Protective effect of Nacetylcysteine against fetal death and preterm labor induced by maternal
inflammation. Am J Obstet Gynecol 188, 203-208 (2003).
57.
Kaga, N., Katsuki, Y., Obata, M. & Shibutani, Y. Repeated administration of
low-dose lipopolysaccharide induces preterm delivery in mice: a model for
human preterm parturition and for assessment of the therapeutic ability of drugs
against preterm delivery. Am J Obstet Gynecol 174, 754-759 (1996).
58.
Lee, P.R. et al. Therapeutic effect of cyclo-oxygenase inhibitors with different
isoform selectivity in lipopolysaccharide-induced preterm birth in mice. Am J
Obstet Gynecol 189, 261-266 (2003).
59.
Gross, G. et al. Inhibition of cyclooxygenase-2 prevents inflammation-mediated
preterm labor in the mouse. American journal of physiology. Regulatory,
integrative and comparative physiology 278, R1415-1423 (2000).
94
60.
Harper, M.J. & Skarnes, R.C. The role of prostaglandin in endotoxin-induced
abortion and fetal death. Adv Biosci 9, 789-793 (1973).
61.
Elovitz, M.A., Wang, Z., Chien, E.K., Rychlik, D.F. & Phillippe, M. A new
model for inflammation-induced preterm birth: the role of platelet-activating
factor and Toll-like receptor-4. Am J Pathol 163, 2103-2111 (2003).
62.
Yoshikawa, M. et al. ASK1 promotes uterine inflammation leading to
pathological preterm birth. Sci Rep 10, 1887 (2020).
63.
Reznikov, L.L. et al. Utilization of endoscopic inoculation in a mouse model of
intrauterine infection-induced preterm birth: role of interleukin 1beta. Biology of
reproduction 60, 1231-1238 (1999).
64.
Furuya, H. et al. Resveratrol Protects Against Pathological Preterm Birth by
Suppression of Macrophage-Mediated Inflammation. Reprod Sci 22, 1561-1568
(2015).
65.
Yamashita, A. et al. Increased tissue levels of omega-3 polyunsaturated fatty
acids prevents pathological preterm birth. Sci Rep 3, 3113 (2013).
66.
Gonzalez, J.M., Franzke, C.W., Yang, F., Romero, R. & Girardi, G. Complement
activation triggers metalloproteinases release inducing cervical remodeling and
preterm birth in mice. Am J Pathol 179, 838-849 (2011).
95
67.
Panigel, M. Placental perfusion experiments. American Journal of Obstetrics and
Gynecology 84, 1664-1683 (1962).
68.
Au - Grafmüller, S., Au - Manser, P., Au - Krug, H.F., Au - Wick, P. & Au - von
Mandach, U. Determination of the Transport Rate of Xenobiotics and
Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion
Model. JoVE, e50401 (2013).
69.
Nagai, M. et al. Characterization of transplacental transfer of paroxetine in
perfused human placenta: development of a pharmacokinetic model to evaluate
tapered dosing. Drug Metab Dispos 41, 2124-2132 (2013).
70.
Karadas, B. et al. Comparison of effects of cyclooxygenase inhibitors on
myometrial contraction and constriction of ductus arteriosus in rats. European
Journal of Pharmacology 485, 289-298 (2004).
71.
Bae, Y. et al. Preparation and biological characterization of polymeric micelle
drug carriers with intracellular pH-triggered drug release property: tumor
permeability, controlled subcellular drug distribution, and enhanced in vivo
antitumor efficacy. Bioconjugate chemistry 16, 122-130 (2005).
96
72.
Vert, P., Bianchetti, G., Marchal, F., Monin, P. & Morselli, P.L. Effectiveness and
pharmacokinetics of indomethacin in premature newborns with patent ductus
arteriosus. European journal of clinical pharmacology 18, 83-88 (1980).
73.
Myllynen, P.K. et al. Kinetics of gold nanoparticles in the human placenta.
Reprod Toxicol 26, 130-137 (2008).
74.
Talelli, M. et al. Core-crosslinked polymeric micelles: Principles, preparation,
biomedical applications and clinical translation. Nano Today 10, 93-117 (2015).
75.
Pyo, K.-h., Lee, D.H., Kim, Y. & Kim, J.-W. Extremely rapid and simple healing
of a transparent conductor based on Ag nanowires and polyurethane with a
Diels–Alder network. Journal of Materials Chemistry C 4, 972-977 (2016).
76.
Rijcken, C.J., Snel, C.J., Schiffelers, R.M., van Nostrum, C.F. & Hennink, W.E.
Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis,
characterisation and in vivo studies. Biomaterials 28, 5581-5593 (2007).
77.
Hu, Y.B., Dammer, E.B., Ren, R.J. & Wang, G. The endosomal-lysosomal
system: from acidification and cargo sorting to neurodegeneration. Transl
Neurodegener 4, 18 (2015).
97
78.
Chang, M.D., Pollard, J.W., Khalili, H., Goyert, S.M. & Diamond, B. Mouse
placental macrophages have a decreased ability to present antigen. Proc Natl
Acad Sci U S A 90, 462-466 (1993).
79.
Phillippe, M. Cell-free fetal DNA--a trigger for parturition. N Engl J Med 370,
2534-2536 (2014).
80.
Rojas-Espinosa, O., Arce-Paredez, P., Dannenberg, A.M. & Kamaenetz, R.L.
Macrophage esterase: identification, purification and properties of a
chymotrypsin-like esterase from lung that hydrolyses and transfers nonpolar
amino acid esters. Biochim Biophys Acta 403, 161-179 (1975).
81.
Needham, L.A. et al. Drug targeting to monocytes and macrophages using
esterase-sensitive chemical motifs. J Pharmacol Exp Ther 339, 132-142 (2011).
82.
Neilson, J.P., West, H.M. & Dowswell, T. Betamimetics for inhibiting preterm
labour. Cochrane Database Syst Rev, Cd004352 (2014).
83.
Raju, T.N., Higgins, R.D., Stark, A.R. & Leveno, K.J. Optimizing care and
outcome for late-preterm (near-term) infants: a summary of the workshop
sponsored by the National Institute of Child Health and Human Development.
Pediatrics 118, 1207-1214 (2006).
98
84.
Petrini, J.R. et al. Increased risk of adverse neurological development for late
preterm infants. J Pediatr 154, 169-176 (2009).
85.
Bennett, P.R., Rose, M.P., Myatt, L. & Elder, M.G. Preterm labor: stimulation of
arachidonic acid metabolism in human amnion cells by bacterial products. Am J
Obstet Gynecol 156, 649-655 (1987).
86.
Petros, R.A. & DeSimone, J.M. Strategies in the design of nanoparticles for
therapeutic applications. Nat Rev Drug Discov 9, 615-627 (2010).
87.
Ragelle, H., Danhier, F., Préat, V., Langer, R. & Anderson, D.G. Nanoparticlebased drug delivery systems: a commercial and regulatory outlook as the field
matures. Expert Opin Drug Deliv 14, 851-864 (2017).
88.
Barenholz, Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J
Control Release 160, 117-134 (2012).
89.
Bertrand, N., Wu, J., Xu, X., Kamaly, N. & Farokhzad, O.C. Cancer
nanotechnology: the impact of passive and active targeting in the era of modern
cancer biology. Advanced drug delivery reviews 66, 2-25 (2014).
90.
Pereira, K.V., Giacomeli, R., Gomes de Gomes, M. & Haas, S.E. The challenge
of using nanotherapy during pregnancy: Technological aspects and biomedical
implications. Placenta 100, 75-80 (2020).
99
91.
Fournier, S.B., D'Errico, J.N. & Stapleton, P.A. Engineered nanomaterial
applications in perinatal therapeutics. Pharmacol Res 130, 36-43 (2018).
92.
de Araújo, T.E. et al. Experimental models of maternal-fetal interface and their
potential use for nanotechnology applications. Cell Biol Int (2019).
93.
Menezes, V., Malek, A. & Keelan, J.A. Nanoparticulate drug delivery in
pregnancy: placental passage and fetal exposure. Curr Pharm Biotechnol 12,
731-742 (2011).
94.
Cartwright, L. et al. In vitro placental model optimization for nanoparticle
transport studies. Int J Nanomedicine 7, 497-510 (2012).
95.
Zhang, B., Liang, R., Zheng, M., Cai, L. & Fan, X. Surface-Functionalized
Nanoparticles as Efficient Tools in Targeted Therapy of Pregnancy
Complications. Int J Mol Sci 20 (2019).
96.
Hua, S. & Vaughan, B. In vitro comparison of liposomal drug delivery systems
targeting the oxytocin receptor: a potential novel treatment for obstetric
complications. Int J Nanomedicine 14, 2191-2206 (2019).
97.
Hua, S. Synthesis and in vitro characterization of oxytocin receptor targeted
PEGylated immunoliposomes for drug delivery to the uterus. J Liposome Res
29, 357-367 (2019).
100
98.
Wathes, D.C., Borwick, S.C., Timmons, P.M., Leung, S.T. & Thornton, S.
Oxytocin receptor expression in human term and preterm gestational tissues
prior to and following the onset of labour. J Endocrinol 161, 143-151 (1999).
99.
Fuchs, A.R., Fuchs, F., Husslein, P. & Soloff, M.S. Oxytocin receptors in the
human uterus during pregnancy and parturition. Am J Obstet Gynecol 150, 734741 (1984).
100.
Thornton, S. et al. Treatment of spontaneous preterm labour with retosiban: a
phase 2 proof-of-concept study. Br J Clin Pharmacol 80, 740-749 (2015).
101.
Goldenberg, R.L. The management of preterm labor. Obstet Gynecol 100, 10201037 (2002).
102.
Ivanisević, M., Djelmis, J. & Buković, D. Review on prostaglandin and oxytocin
activity in preterm labor. Coll Antropol 25, 687-694 (2001).
103.
Buckingham, J.C., Selden, R. & Danforth, D.N. Connective tissue changes in
the cervix during pregnancy and labor. Ann N Y Acad Sci 97, 733-742 (1962).
104.
Uldbjerg, N., Ekman, G., Malmström, A., Olsson, K. & Ulmsten, U. Ripening of
the human uterine cervix related to changes in collagen, glycosaminoglycans,
and collagenolytic activity. Am J Obstet Gynecol 147, 662-666 (1983).
101
105.
Huszar, G. Biology and biochemistry of myometrial contractility and cervical
maturation. Semin Perinatol 5, 216-235 (1981).
106.
Calder, A.A. Prostaglandins and biological control of cervical function. Aust N Z
J Obstet Gynaecol 34, 347-351 (1994).
107.
Bakker, R., Pierce, S. & Myers, D. The role of prostaglandins E1 and E2,
dinoprostone, and misoprostol in cervical ripening and the induction of labor: a
mechanistic approach. Arch Gynecol Obstet 296, 167-179 (2017).
108.
Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and
the antitumor agent smancs. Cancer Res 46, 6387-6392 (1986).
109.
Lahra, M.M. & Jeffery, H.E. A fetal response to chorioamnionitis is associated
with early survival after preterm birth. Am J Obstet Gynecol 190, 147-151
(2004).
110.
Nadeau-Vallée, M. et al. Sterile inflammation and pregnancy complications: a
review. Reproduction 152, R277-r292 (2016).
111.
Romero, R. et al. Prevalence and clinical significance of sterile intra-amniotic
inflammation in patients with preterm labor and intact membranes. Am J Reprod
Immunol 72, 458-474 (2014).
102
112.
Yoneda, S. et al. Antibiotic Therapy Increases the Risk of Preterm Birth in
Preterm Labor without Intra-Amniotic Microbes, but may Prolong the Gestation
Period in Preterm Labor with Microbes, Evaluated by Rapid and High-Sensitive
PCR System. Am J Reprod Immunol 75, 440-450 (2016).
113.
Bredeson, S. et al. HMGB1 promotes a p38MAPK associated non-infectious
inflammatory response pathway in human fetal membranes. PLoS One 9,
e113799 (2014).
114.
Puchner, K. et al. Mid-trimester amniotic fluid interleukins (IL-1β, IL-10 and IL18) as possible predictors of preterm delivery. In Vivo 25, 141-148 (2011).
115.
Jakobsen, T.R., Clausen, F.B., Rode, L., Dziegiel, M.H. & Tabor, A. High levels
of fetal DNA are associated with increased risk of spontaneous preterm delivery.
Prenat Diagn 32, 840-845 (2012).
116.
Farina, A. et al. High levels of fetal cell-free DNA in maternal serum: a risk
factor for spontaneous preterm delivery. Am J Obstet Gynecol 193, 421-425
(2005).
117.
Leung, T.N., Zhang, J., Lau, T.K., Hjelm, N.M. & Lo, Y.M. Maternal plasma
fetal DNA as a marker for preterm labour. Lancet 352, 1904-1905 (1998).
103
118.
Friel, L.A. et al. The calcium binding protein, S100B, is increased in the
amniotic fluid of women with intra-amniotic infection/inflammation and preterm
labor with intact or ruptured membranes. J Perinat Med 35, 385-393 (2007).
119.
Yang, D., Han, Z. & Oppenheim, J.J. Alarmins and immunity. Immunol Rev
280, 41-56 (2017).
120.
Koga, K. & Mor, G. Toll-like receptors at the maternal-fetal interface in normal
pregnancy and pregnancy disorders. Am J Reprod Immunol 63, 587-600 (2010).
121.
Lappas, M. NOD1 and NOD2 regulate proinflammatory and prolabor mediators
in human fetal membranes and myometrium via nuclear factor-kappa B. Biol
Reprod 89, 14 (2013).
122.
Matzinger, P. Tolerance, danger, and the extended family. Annu Rev Immunol
12, 991-1045 (1994).
123.
Kato, M. et al. Inappropriate activation of invariant natural killer T cells and
antigen-presenting cells with the elevation of HMGB1 in preterm births without
acute chorioamnionitis. Am J Reprod Immunol, e13330 (2020).
124.
Allen, T.M. & Everest, J.M. Effect of liposome size and drug release properties
on pharmacokinetics of encapsulated drug in rats. J Pharmacol Exp Ther 226,
539-544 (1983).
104
125.
Allen, T.M., Murray, L., MacKeigan, S. & Shah, M. Chronic liposome
administration in mice: effects on reticuloendothelial function and tissue
distribution. J Pharmacol Exp Ther 229, 267-275 (1984).
126.
Klibanov, A.L., Maruyama, K., Torchilin, V.P. & Huang, L. Amphipathic
polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS
Lett 268, 235-237 (1990).
127.
Choi, H.S. et al. Renal clearance of quantum dots. Nat Biotechnol 25, 1165-1170
(2007).
128.
Miyata, K., Christie, R.J. & Kataoka, K. Polymeric micelles for nano-scale drug
delivery. Reactive and Functional Polymers 71, 227-234 (2011).
129.
Vermillion, S.T., Scardo, J.A., Lashus, A.G. & Wiles, H.B. The effect of
indomethacin tocolysis on fetal ductus arteriosus constriction with advancing
gestational age. American journal of obstetrics and gynecology 177, 256-259;
discussion 259-261 (1997).
130.
Momma, K. & Takao, A. In vivo constriction of the ductus arteriosus by
nonsteroidal antiinflammatory drugs in near-term and preterm fetal rats.
Pediatric research 22, 567-572 (1987).
105
131.
Coceani, F., White, E., Bodach, E. & Olley, P.M. Age-dependent changes in the
response of the lamb ductus arteriosus to oxygen and ibuprofen. Can J Physiol
Pharmacol 57, 825-831 (1979).
132.
Clyman, R.I. Developmental responses to oxygen, arachidonic acid, and
indomethacin in the fetal lamb ductus arteriosus in vitro. Prostaglandins Med 1,
167-174 (1978).
133.
Reese, J., Anderson, J.D., Brown, N., Roman, C. & Clyman, R.I. Inhibition of
cyclooxygenase isoforms in late- but not midgestation decreases contractility of
the ductus arteriosus and prevents postnatal closure in mice. American journal of
physiology. Regulatory, integrative and comparative physiology 291, R17171723 (2006).
134.
Moise, K.J., Jr. et al. Indomethacin in the treatment of premature labor. Effects
on the fetal ductus arteriosus. N Engl J Med 319, 327-331 (1988).
135.
Sawdy, R.J., Lye, S., Fisk, N.M. & Bennett, P.R. A double-blind randomized
study of fetal side effects during and after the short-term maternal administration
of indomethacin, sulindac, and nimesulide for the treatment of preterm labor.
American journal of obstetrics and gynecology 188, 1046-1051 (2003).
106
136.
Respondek, M., Weil, S.R. & Huhta, J.C. Fetal echocardiography during
indomethacin treatment. Ultrasound Obstet Gynecol 5, 86-89 (1995).
137.
Savage, A.H., Anderson, B.L. & Simhan, H.N. The safety of prolonged
indomethacin therapy. Am J Perinatol 24, 207-213 (2007).
138.
Gardner, M.O., Owen, J., Skelly, S. & Hauth, J.C. Preterm delivery after
indomethacin. A risk factor for neonatal complications? J Reprod Med 41, 903906 (1996).
139.
Vermillion, S.T. & Newman, R.B. Recent indomethacin tocolysis is not
associated with neonatal complications in preterm infants. Am J Obstet Gynecol
181, 1083-1086 (1999).
140.
Niebyl, J.R. & Witter, F.R. Neonatal outcome after indomethacin treatment for
preterm labor. Am J Obstet Gynecol 155, 747-749 (1986).
141.
Sharpe, G.L., Larsson, K.S. & Thalme, B. Studies on closure of the ductus
arteriosus. XII. In utero effect of indomethacin and sodium salicylate in rats and
rabbits. Prostaglandins 9, 585-596 (1975).
142.
Brash, A.R. et al. Pharmacokinetics of indomethacin in the neonate. Relation of
plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med
305, 67-72 (1981).
107
143.
Smyth, J.M. et al. Intravenous indometacin in preterm infants with symptomatic
patent ductus arteriosus. A population pharmacokinetic study. Br J Clin
Pharmacol 58, 249-258 (2004).
144.
Thalji, A.A. et al. Pharmacokinetics of intravenously administered indomethacin
in premature infants. J Pediatr 97, 995-1000 (1980).
145.
Yeh, T.F., Achanti, B., Patel, H. & Pildes, R.S. Indomethacin therapy in
premature infants with patent ductus arteriosus--determination of therapeutic
plasma levels. Dev Pharmacol Ther 12, 169-178 (1989).
146.
Erlich, J. et al. Tissue factor is required for uterine hemostasis and maintenance
of the placental labyrinth during gestation. Proc Natl Acad Sci U S A 96, 81388143 (1999).
147.
Dupressoir, A., Lavialle, C. & Heidmann, T. From ancestral infectious
retroviruses to bona fide cellular genes: role of the captured syncytins in
placentation. Placenta 33, 663-671 (2012).
148.
Wick, P. et al. Barrier capacity of human placenta for nanosized materials.
Environ Health Perspect 118, 432-436 (2010).
108
謝辞
本研究の遂行に際し、研究のご支援、ご指導を賜りました東京大学医学部産
科婦人科 主任教授 藤井知行先生、教授 大須賀穣先生に深謝申し上げます。
また、研究課題の立案から論文執筆に至るまで直接ご指導を賜りました東京
大学医学部産科婦人科 講師 入山高行先生に深く感謝の意を表します。
東京大学医学部産科婦人科
准教授 永松健先生、講師 熊澤惠一先生、吉川
美登里先生、松井遥香先生、稲岡直子先生にはご指導、ご助言、ご協力を賜り
ました。
東京大学大学院工学系研究科バイオエンジニアリング専攻 准教授 Cabral
Horacio 先生、宮崎 拓也先生はじめ、同研究室の先生方には高分子ミセルの作
成から論文の執筆に至るまで、ご指導、多大なるご協力、ご助言をいただきま
した。深く感謝申し上げます。
109
...
論文の公開元へ
